Valuation: Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.67B 4.35B 3.97B 7.48B 506B 7.55B 52.75B 20.44B 258B 19.72B 19.29B 829B P/E 2024
-20x
P/E 2025 146x
Enterprise Value 5.26B 4.67B 4.36B 3.97B 7.49B 506B 7.56B 52.82B 20.47B 258B 19.74B 19.32B 830B EV / Sales 2024
5.15x
EV / Sales 2025 3.17x
Free-Float
88.57%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+1.53%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Chief Operating Officer 56 2009-09-24
Director of Finance/CFO 55 2017-09-30
Chief Tech/Sci/R&D Officer - 2025-08-24
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Tender

Director

-63,416 0.0496%
5/14/26 Tender

Director

-297,904 0.2330%
5/14/26 Tender

General Counsel

-928,388 0.7263%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+77.54%+10.47% 5.25B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.69%-3.08%+32.21%+52.48% 370.24B
Weighted average by Cap. -0.60%-3.32%+30.58%+68.87%

Financials

2024 2025
Net sales 781M 695M 647M 590M 1.11B 75.25B 1.12B 7.85B 3.04B 38.37B 2.93B 2.87B 123B 1B 892M 832M 758M 1.43B 96.66B 1.44B 10.08B 3.91B 49.29B 3.77B 3.69B 158B
Net income -198M -176M -164M -149M -282M -19.06B -285M -1.99B -770M -9.72B -743M -727M -31.23B 22.39M 19.9M 18.55M 16.91M 31.9M 2.16B 32.2M 225M 87.14M 1.1B 84.05M 82.23M 3.53B
Net Debt 53.65M 47.68M 44.45M 40.52M 76.43M 5.17B 77.16M 539M 209M 2.63B 201M 197M 8.47B 6.57M 5.84M 5.45M 4.96M 9.37M 633M 9.45M 66.02M 25.59M 323M 24.68M 24.14M 1.04B
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. APLS Stock